Physician profile
Michael D Jones
NPI 1538173422
$1,650.63
in general payments reported to CMS, 2019-2025
30 companies · $623 in 2025
The $623 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.03 · 2020: $49.10 · 2021: $93.12 · 2022: $132 · 2023: $310 · 2024: $376 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $578.39 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $121.30 | 2019-2025 | Airsupra |
| Lilly USA, LLC | $79.89 | 2020-2025 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $72.50 | 2022-2024 | Repatha, Otezla, Prolia |
| Axsome Therapeutics, INC. | $68.42 | 2022-2025 | Auvelity, Sunosi |
| Inspire Medical Systems, INC. | $63.47 | 2024-2025 | Inspire |
| Organon LLC | $62.35 | 2021-2025 | Nexplanon |
| Novo Nordisk INC | $56.06 | 2020-2025 | Ozempic |
| Medtronic, INC. | $55.52 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Abbott Laboratories | $41.74 | 2023 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.57 | 2025 | Caplyta |
| Neuronetics, INC. | $35.00 | 2025 | Neurostar Tms Therapy System |
| Gilead Sciences, INC. | $33.59 | 2019-2025 | |
| Pfizer INC. | $33.56 | 2024-2025 | |
| Glaxosmithkline, LLC. | $31.34 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $27.56 | 2021-2024 | Dexcom G6 Transmitter |
| Corium, LLC | $25.18 | 2024 | Azstarys |
| Neurocrine Biosciences, INC. | $23.47 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.66 | 2025 | |
| Tris Pharma INC | $20.38 | 2024 | Dyanavel Xr |
| Kyowa Kirin, INC. | $19.82 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.62 | 2025 | |
| Ascensia Diabetes Care US INC. | $18.28 | 2025 | |
| Idorsia Pharmaceuticals US INC | $17.57 | 2024 | Quviviq |
| Allergan, INC. | $16.43 | 2019 | |
| Sumitomo Pharma America, INC. | $15.41 | 2023 | Gemtesa |
| Dynavax Technologies Corporation | $14.20 | 2025 | Heplisav-B |
| Merck Sharp & Dohme LLC | $14.12 | 2024 | Vaxneuvance, Gardasil 9, Capvaxive |
| Sanofi Pasteur INC. | $14.03 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.20 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.